A predictive model for aggressive non-Hodgkin’s lymphoma: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94. Abstract

Cabanillas F et al. Molecular responses with FND + Rituxan chemo-inmmunotherapy for stage IV indolent follicular non-Hodgkin’s lymphoma. Blood 2000;96(330a);No abstract available

Cheung MC et al. Rituximab for indolent lymphoma: An analysis of outcomes in a large population-wide study. Proc ASH 2003;Abstract 5754

Czuczman MS et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22(23):4711-6. Abstract

Czuczman MS et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17(1):268-76. Abstract

Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkins lymphoma. Semin Oncol 2003;30(1 Suppl 2):9-15. Abstract

Hainsworth JD et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin’s lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(7);[Epub ahead of print]. Abstract

Horning SJ. Follicular lymphoma: Have we made any progress? Ann Oncol 2000;11(Suppl 1):23-7. Abstract

Lossos IS et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350(18):1828-37. Abstract

MacDermed D et al. Extranodal nonorbital indolent lymphomas of the head and neck: Relationship between tumor control and radiotherapy. Int J Radiot Oncol Biol Phys 2004;59(3):788-95. Abstract

McLaughlin P et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000;27(6 Suppl 12):37-41. Abstract

McLaughlin P et al. Stage IV indolent lymphoma: A randomized study of concurrent vs sequential use of FND (fludarabine, mitoxantrone, dexamethasone) and rituximab monoclonal antibody therapy, with interferon maintenance. Proc ASCO 2003;Abstract 2269.

Solal-Celigny et al. Follicular lymphoma international prognostic index. Blood 2004;140(5):1258-65. Abstract

Zinzani PL et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22(13):2654-61. Abstract